Kimberly-Clark KMB
Consumer Defensive · Household & Personal Products · Synthos Deep Dive · 2026-07-03
The Overview
Kimberly-Clark makes the everyday paper-and-care products in your bathroom and under your sink: Huggies diapers, Kleenex tissues, Scott and Cottonelle toilet paper, Kotex, Depend, and Poise. People buy these in good times and bad, so the business is steady and the stock barely moves with the market. It pays a reliable, growing dividend (about 4.4% a year, raised for over five decades).
The problem: these are slow-growth products. Sales grow maybe 2–3% a year, and the company already sells to almost everyone, so it's hard to grow much faster. The stock is priced about fairly to slightly expensive — Wall Street's average price target is actually a little below today's price. On top of that, Kimberly-Clark is taking on a lot of debt to buy another company (Kenvue, the maker of Tylenol, Band-Aid, and Neutrogena), which is a big, risky change.
Our verdict is Watch — a fine, safe dividend stock to own for income, but not cheap enough and not growing enough to be a table-pounding buy right now.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle). The products are recession-proof and the stock is calm, but the company carries meaningful debt and is about to add more.
- Growth Quality 4/10 (below average). It grows slowly — this is a steady tortoise, not a racehorse.
- Exponential Potential 2/10 (low). Do not expect this stock to double. It's a mature giant in saturated markets.
The one big worry: the Kenvue deal. If it costs too much, adds too much debt, or is hard to digest, the "safe dividend stock" story gets shakier.
Putting a number on it: our fair-value estimate is $113 against a current price of $109.55 — real upside if our numbers are right.
Our summary metrics
Low beta (0.30) & staple demand, but net-debt/EBITDA 2.1×, thin equity, and a large debt-funded Kenvue deal add risk.
Low-single-digit organic growth, ~2% forward EPS CAGR pre-deal, flat margins — a slow compounder, not a grower.
Mature staple in structural low-growth categories; no acceleration and a $38B cap in a saturated TAM — minimal multibagger optionality.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature staple in structural low-growth categories; no acceleration and a $38B cap in a saturated TAM — minimal multibagger optionality.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $106.5 (high $121 / low $99; 0 Strong Buy · 10 Buy · 18 Hold · 3 Sell → "Hold") — context, and notably below the current price |
| Valuation | 18.0× trailing EPS · 15.2× FY26E · 15.1× FY27E · 12.6× FY30E · EV/S 2.7× · EV/EBITDA 14.6× |
| Technicals | Above 50/200-DMA and +18% 3-mo, but RSI 78 (overbought) and −12.8% over 12 mo (SPY +20.6%) |
| Conviction | Low — 0 net-bullish voices, 0 traceable claims; call rests entirely on fundamentals + quant |
| Position sizing | Income/defensive sleeve only, ~1–2% starter if at all; not a conviction position |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for KMB — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $109.55, 0% above the 50-day average ($109), 6% above the 200-day average ($103) — an uptrend. 16% below the 52-week high of $131, 18% above the 52-week low of $93.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $109.55 is currently inside the band (band $107–$112).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 50.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.03, negative momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = KMB · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Kimberly-Clark (NASDAQ: KMB) is a ~150-year-old (founded 1872) global maker of personal-care and tissue products, headquartered in Dallas, TX, run by Chairman & CEO Mike Hsu. Its brand shelf is one of the most recognizable in the consumer-staples world: Huggies, Pull-Ups, GoodNites (baby/child care); Kotex, Poise, Depend (feminine & incontinence); Kleenex, Scott, Cottonelle, Viva (tissue & towel); and Wypall/KleenGuard (professional/away-from-home). Fiscal year ends December 31.
An important structural change frames the numbers: KMB has re-segmented into North America and International Personal Care (IPC), and reports the International Family Care & Professional (IFP) business as discontinued operations. That is why FY2025 "continuing" revenue prints at $17.22B versus FY2024's $20.06B — it is a narrower reporting base, not a 14% collapse in the underlying business.
Revenue mix (FY2025 continuing ops, from filings):
- By product line: Diapers $6.77B · Consumer tissue $4.06B · Adult care $1.95B · Away-from-Home Professional $1.84B · Feminine care $1.71B. Diapers + tissue are ~63% of the base — big, mature, private-label-exposed categories.
- By geography (partial disclosure): the FMP geographic feed only tags United States $10.1B for FY2025; the balance is international (Latin America and Asia are the historically faster-growing pieces). The business is roughly split US / international, with IPC the growth engine.
The strategic pivot is explicit and large: management is redeploying around "Powering Care" and, most consequentially, has agreed to acquire Kenvue (the consumer-health spin-out of J&J — Tylenol, Band-Aid, Neutrogena, Listerine). That deal, not organic tissue volume, is the defining variable for the next few years (§9, §11).
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of KMB in the Synthos knowledge base. total_claims = 0; net-bullish voices = 0; there are no claim_ids to cite. Per house standard we will not manufacture conviction we cannot trace.
That absence is itself information: KMB is a mature, widely-owned dividend staple, not the kind of forward-exponential or contested growth name that the KB's expert panel (podcasters, fund managers, operators) tends to debate. The verdict here is therefore fundamentals- and quant-driven only, and is scored more conservatively for it — we do not give a name credit for conviction we cannot reconcile.
For external context (not Synthos conviction), the sell-side consensus is "Hold": 0 Strong Buy, 10 Buy, 18 Hold, 3 Sell, with a price target of $106.5 — below the current $114.72. That is a market that sees KMB as fairly valued at best.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Beta 0.30 and non-cyclical staple demand cushion the downside, but net-debt/EBITDA 2.1×, razor-thin book equity ($1.5B; P/B 21×), and a large debt-funded Kenvue deal raise balance-sheet and integration risk. |
| Growth Quality | 4 · Below-Average | Q1'26 organic sales +2.5%, forward EPS CAGR only ~2% on the pre-deal base (FY26E $7.53 → FY27E $7.57), gross margin ~36–38% and roughly flat. High ROIC (~15%) and a durable brand moat keep it off the floor, but this is a slow compounder. |
| Exponential Potential | 2 · Low | Saturated, low-growth categories (diapers, tissue), no positive acceleration, and a $38B cap in a mature TAM. There is no realistic path to a multibagger; the "growth" is a dividend plus buybacks. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Kenvue closes and is cleanly accretive; organic growth holds ~3%+; productivity ("Powering Care") lifts margins; market re-rates the combined platform. FY27E EPS ~$8.2 on a ~17× multiple (modest premium for a bigger, more diversified staple). | ~$140 (+22%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$7.6; low-single-digit organic growth; deal integration is a wash near-term; a defensive staple with a 4.4% yield holds a ~15× multiple. | ~$113 (−1%) |
| Bear | Kenvue integration drags, leverage strains the dividend-growth story, private-label pressure and input-cost inflation squeeze margins. FY27E EPS ~$6.8; multiple de-rates to ~12.5×. | ~$88 (−23%) |
Synthos fair value = the base case, ~$113 (−1%), with the full $88–$140 span as the honest range. Our base sits above the Street's $106.5 target (we give some credit to the deal and to productivity), while our bear takes leverage and integration seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures. Net: priced for what it is; the risk/reward is roughly symmetric-to-slightly-negative, which is why the verdict is Watch, not Buy.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). KMB is firmly in the first bucket and near the bottom of the exponential scale:
- Forward growth: organic sales +2.5% in Q1'26; pre-deal EPS CAGR ~2% (FY26E $7.53 → FY28E $8.14). The step-up in FY28–FY30 consensus revenue ($18.3B → $26.7B → $36B) is largely the Kenvue consolidation, not organic acceleration — it is M&A math, and should be read as such.
- Acceleration (2nd derivative): essentially zero organically. These are saturated categories (diapers face declining birth rates in developed markets; tissue is a share-and-price game). There is no demand inflection to ride.
- Room to run: at $38B in mature TAMs, there is no law-of-large-numbers and no whitespace working in the stock's favor. A multibagger would require a valuation re-rating that staples rarely get.
- Reinvestment runway: capex is a routine ~$1.1B/yr maintenance-and-productivity spend; the "growth" reinvestment is now the Kenvue check, which is an M&A bet rather than organic reinvestment at high incremental ROIC.
Exponential Potential: Low (2/10). Own KMB, if at all, for income and stability — a 4.4% yield with a Dividend-King track record — not for capital appreciation. Per our flagship philosophy, we pick forward next-exponentials over trailing compounders; KMB is neither exponential nor a fast compounder, so it does not belong in a growth or flagship sleeve.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 continuing-ops $17.22B (narrower base after IFP moved to discontinued ops; FY24 was $20.06B on the old basis). Q1'26 net sales $4.16B, +2.7% (organic +2.5%). This is a low-single-digit top line.
- Margins: gross ~35.9% TTM (36.8% Q1'26 reported, 37.9% adjusted), EBITDA margin ~18.5%, operating ~13.3%, net ~12.8% TTM. Solid for a staple, roughly flat trend — productivity savings are largely reinvested in price/innovation.
- Earnings: FY25 net income $2.02B, EPS $6.08 (diluted $6.07); TTM net income/share ~$6.38. Q1'26 diluted EPS $2.00 (adjusted $1.97, +2.1%). Note continuing-ops adjusted EPS was down 1.2% on a higher tax rate — the growth is not robust.
- Cash flow: FY25 operating CF $2.78B, capex −$1.14B, FCF ~$1.64B (FCF yield ~4.3%). FCF fully covers the $1.66B dividend but leaves little cushion — the payout ratio is high (~79% of earnings).
- Balance sheet: total debt $7.30B, net debt $6.61B, net-debt/EBITDA ~2.1×. Book equity is a thin $1.5B (P/B ~21×, ROE optically inflated to ~144% by the small denominator) — a legacy of years of buybacks. Current ratio 0.77×. This is a levered staple, and the Kenvue deal will add more debt.
6. Valuation — priced in or room?
KMB is fairly valued to slightly full, not cheap and not egregious. On trailing numbers it trades at 18.0× EPS, 2.7× EV/sales, 14.6× EV/EBITDA — roughly in line with the staples group. On forward consensus the P/E is 15.2× (FY26E) → 15.1× (FY27E) → 12.6× (FY30E), but note the FY30 compression is flattered by Kenvue-driven earnings, not organic growth. The PEG is unattractive: a ~15× forward multiple against ~2% organic EPS growth is not a bargain. The FMP letter rating is B+ (score 3/5) with weak marks on debt-to-equity (1/5) and price-to-book (1/5).
Street targets (context, and a cautionary one): consensus $106.5, high $121, low $99 — the average target sits below the $114.72 price, i.e. the sell-side thinks the stock is slightly ahead of itself. Our base FV of ~$113 is a touch more constructive than consensus (crediting productivity and the deal's optionality) but still implies essentially no upside from here. This is a hold-for-yield valuation, not a value entry.
7. Technicals (from the tech block)
- Trend: constructive. $114.72 sits above the 50-DMA ($100.25) and 200-DMA ($104.89), with MACD positive (+3.48) — a recovering uptrend after a weak year.
- Location: −16.1% off the 52-week high ($136.77) and +23.3% off the 52-week low ($93.05); the max drawdown from peak was −27.8% — deeper than a "sleepy staple" reputation implies, a reminder that even KMB de-rates when growth disappoints.
- Momentum: RSI(14) 78.4 — overbought (>70). The recent +18% 3-month pop (partly the Kenvue-deal reaction) has stretched the entry. This argues against chasing here.
- Relative strength (the tell): KMB −12.8% over 12 months vs SPY +20.6% and QQQ +30.3% — a large laggard over the year, even after a strong 3-month (+17.6% vs SPY +13.7%). The 12-month picture is defensive underperformance.
- Read: the trend has turned up but momentum is overbought; a patient buyer waits for RSI to cool and a pullback toward the rising 50-DMA (~$100) rather than paying up near $115 into a 78 RSI.
8. Moat & competitive position
KMB's moat is brand strength + scale distribution in staples: Huggies, Kleenex, Scott, Kotex and Depend are category-leading names with shelf-space and retailer relationships that are hard to dislodge. That yields pricing power within limits and high returns on capital (ROIC ~15%). But the moat is shallow relative to the threats: private label competes aggressively in tissue and diapers, retailers (Walmart, Costco, Amazon) hold buyer power, and input costs (pulp, resin, energy) plus FX swing margins. The categories themselves are low-growth to declining (developed-market birth rates pressure diapers).
Peer set (FMP, market cap): Kenvue $38.1B (the acquisition target — Tylenol/Band-Aid/Neutrogena), Church & Dwight $23.4B, Hershey $36.9B, Keurig Dr Pepper $45.3B, Kellanova $29.0B, Estée Lauder $30.3B, Sysco $40.6B, Archer-Daniels-Midland $37.0B, Ambev $48.3B, JBS $27.2B. Within staples KMB is a mid-cap, mature, higher-leverage name; the direct household/personal-care comps (CHD, and post-deal KVUE) are the relevant frame. KMB does not command a premium growth multiple, and shouldn't.
9. Management, capital allocation & guidance
- Capital allocation: dividend-first. KMB is a Dividend King (50+ years of increases), paying ~$1.66B/yr (4.4% yield, ~79% payout) with modest buybacks (~$0.14B in FY25). The defining capital decision is now the Kenvue acquisition — a large, debt-funded bet that shifts KMB from pure tissue/personal-care toward consumer health. This is transformational and unproven; it can diversify and re-rate the platform or strain the balance sheet and distract management.
- Insider activity: the sampled Form-4 window (through 2026-05-06) shows routine officer activity — RSU awards/vesting and small associated sales (e.g., Controller Andrew Scribner sold 4,095 sh at ~$98; IPC President Katy Chen small sales around award vesting). No alarming discretionary selling cluster; ordinary compensation mechanics.
- Management's own guidance (half-weighted — their own book): the SEC 8-K earnings release (filed 2026-04-28, Q1'26) is a real earnings release and reaffirms the 2026 outlook. In management's words, they "delivered solid volume-plus-mix performance" with net sales +2.7% (organic +2.5%), adjusted gross margin 37.9% (−60 bps), adjusted operating profit +3.7%, and adjusted EPS from continuing operations $1.60 (−1.2%) on a higher tax rate. CEO Mike Hsu framed the year around "Powering Care" and "the unique, generational value creation opportunity ahead with the acquisition of Kenvue," with a large innovation lineup launching in Q2. We half-weight this — it is management talking its own book, and the adjusted continuing-ops EPS decline is a useful reality check against the upbeat tone. A specific full-year EPS guidance figure was not captured in the ingested text beyond the reaffirmation, so we do not put a precise number on management's outlook.
10. Catalysts & what to watch
- Next earnings: 2026-07-28 (Q2'26; Street EPS $1.99, revenue ~$4.24B). Watch organic growth, adjusted gross margin vs input costs, and any updated Kenvue-deal commentary.
- Kenvue acquisition: the single biggest swing factor — deal terms, financing/leverage, regulatory path, close timing, and accretion math. This defines the multi-year story.
- Organic sales & pricing: whether the Q2 innovation lineup lifts volume-plus-mix above ~3% or private-label/pricing pressure caps it.
- Margin & productivity: the "2024 Transformation Initiative" savings vs input-cost and FX headwinds.
- Dividend: continuation of the King streak against a higher post-deal debt load.
Thesis tripwires (what would change the call): Kenvue terms that push net-debt/EBITDA materially above ~3× or threaten the dividend-growth cadence; two quarters of organic growth below ~1%; adjusted gross-margin erosion below ~36%; or a sustained break below the 200-DMA on deal disappointment. A pullback to the low-$100s with the deal de-risked would be a more attractive entry.
11. Key risks
- Kenvue integration & leverage (structural, the big one): a large debt-funded acquisition outside the pure-play core; execution, financing, and dilution/leverage risk. This is the dominant variable.
- Structural low growth: saturated, low-to-declining categories (diapers, tissue) — limited organic upside even if executed well.
- Private label & retailer power: value-conscious consumers and concentrated retail buyers (Walmart/Costco/Amazon) pressure price and share.
- Input-cost & FX volatility: pulp, resin, energy, and currency swings move margins on a thin ~18% EBITDA base.
- Balance-sheet thinness: net-debt/EBITDA ~2.1× (pre-deal) and only $1.5B book equity leave less cushion than the "safe staple" label suggests; a high ~79% payout limits flexibility.
- Valuation: trades slightly above the Street target with a full-to-fair multiple against ~2% organic growth — little margin of safety.
- No expert corroboration: zero Synthos KB coverage — the call has no independent conviction layer, only fundamentals and quant.
12. Verdict, position sizing & monitoring
Watch. KMB is a genuinely durable, low-beta, Dividend-King staple with strong brands and ~$1.6B of free cash flow — a defensible income holding. But it is a slow grower in saturated categories (Growth 4), with minimal appreciation optionality (Exponential 2), carrying real leverage and a large, unproven, debt-funded Kenvue deal (Risk 5) — and it trades slightly above both the Street's $106.5 target and our ~$113 base fair value, with an overbought RSI of 78. The risk/reward is roughly balanced-to-slightly-negative from here. There is no expert coverage in the Synthos KB, so nothing lifts this above a fundamentals-driven Watch.
- Sizing: income/defensive sleeve only, ~1–2% if desired, ideally on a pullback toward the low-$100s and with the Kenvue deal de-risked — not chased near $115 into a 78 RSI. Not a conviction or flagship position.
- Monitoring: re-underwrite on the tripwires in §10; formal re-score at Q2'26 earnings (2026-07-28) and on any Kenvue milestone. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $114.72.
- Single biggest risk: the debt-funded Kenvue acquisition — integration, leverage, and a strategic bet outside the core.
Provenance & disclosures
- Traceability: 0 KB claims — no expert coverage for KMB. The verdict is explicitly fundamentals- and quant-driven; no conviction is borrowed from voices we cannot cite. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here there are simply no claims to reconcile.
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates. Note FY28+ consensus revenue reflects the pending Kenvue consolidation, not organic growth.
- Management caveat: the Q1'26 8-K guidance summarized in §9 is management's own book, half-weighted by design; the adjusted continuing-ops EPS decline (−1.2%) tempers the upbeat tone.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").